Mylan’s (MYL) “Buy” Rating Reiterated at Citigroup
Mylan (NASDAQ:MYL)‘s stock had its “buy” rating reaffirmed by investment analysts at Citigroup in a note issued to investors on Thursday. They currently have a $58.00 price objective on the stock, up from their previous price objective of $48.00. Citigroup’s target price would indicate a potential upside of 34.45% from the company’s previous close.
Several other research analysts also recently commented on the company. Leerink Swann began coverage on Mylan in a research note on Tuesday. They set a “market perform” rating and a $44.00 target price for the company. Cantor Fitzgerald set a $41.00 price objective on Mylan and gave the company a “hold” rating in a research note on Tuesday, December 26th. BidaskClub raised Mylan from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 19th. Guggenheim started coverage on shares of Mylan in a research report on Tuesday, December 12th. They set a “buy” rating and a $59.00 target price for the company. Finally, UBS Group set a $46.00 target price on shares of Mylan and gave the company a “buy” rating in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $43.20.
Mylan (NASDAQ:MYL) traded up $0.03 on Thursday, reaching $43.14. 6,735,500 shares of the company traded hands, compared to its average volume of 6,744,200. Mylan has a 1-year low of $29.39 and a 1-year high of $45.87. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The company has a market capitalization of $23,140.00, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.38.
A number of hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. boosted its position in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after acquiring an additional 1,475 shares during the last quarter. BT Investment Management Ltd bought a new stake in shares of Mylan during the 3rd quarter valued at about $142,000. Doliver Capital Advisors LP bought a new stake in shares of Mylan during the 2nd quarter valued at about $201,000. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Mylan during the 2nd quarter valued at about $210,000. Finally, Loews Corp bought a new stake in Mylan in the 2nd quarter worth approximately $223,000. 74.90% of the stock is owned by institutional investors and hedge funds.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.